Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory t cells and natural killer cells in healthy volunteers

Molecular Therapy

Volumn 22, Issue 7, 2014, Pages 1388-1395

  Ito, Sawa ^a   Bollard, Catherine M ^b   Carlsten, Mattias ^a   Melenhorst, Jan Joseph ^a,d   Biancotto, Angélique ^c   Wang, Ena ^c,e   Chen, Jinguo ^c   Kotliarov, Yuri ^c   Cheung, Foo ^c   Xie, Zhi ^c,f   Marincola, Francesco ^c,f   Tanimoto, Kazushi ^a,g   Battiwalla, Minoo ^a   Olnes, Matthew J ^a,c,h   Perl, Shira ^c   Schum, Paula ^c   Hughes, Thomas E ^c   Keyvanfar, Keyvan ^a   Hensel, Nancy ^a   Muranski, Pawel ^a   Young, Neal S ^a,c   Barrett, A John ^a   more..

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^f SUN YAT SEN UNIVERSITY   (China)

^g EHIME UNIVERSITY   (Japan)

^h ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; INTERLEUKIN 12;

ADULT; ANOREXIA; CELL EXPANSION; CHILL; CISH GENE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOXP3 GENE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IL 2RA GENE; IMMUNOBIOLOGY; IMMUNOCOMPETENCE; IMMUNOMODULATION; INJECTION SITE REACTION; IRRITABILITY; LOW DRUG DOSE; MALE; MYALGIA; NATURAL KILLER CELL; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PROTEIN BLOOD LEVEL; PROTEOMICS; REGULATORY T LYMPHOCYTE; VOMITING; DRUG EFFECTS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84903777370     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.50     Document Type: Conference Paper

References (48)

1. Morgan, DA, Ruscetti, FW and Gallo, R (1976). Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007-1008
2. Smith, KA (1988). Interleukin-2: Inception, impact, and implications. Science 240: 1169-1176
3. Macdonald, D, Jiang, YZ, Gordon, AA, Mahendra, P, Oskam, R, Palmer, PA et al. (1990). Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: A pilot study. Leuk Res 14: 967-973
4. Fehniger, TA, Bluman, EM, Porter, MM, Mrózek, E, Cooper, MA, VanDeusen, JB et al. (2000). Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 106: 117-124. (Pubitemid 30437247
5. Ahmadzadeh, M and Rosenberg, SA (2006). IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107: 2409-2414. (Pubitemid 43345561
6. Sim, GC, Martin-Orozco, N, Jin, L, Yang, Y, Wu, S, Washington, E et al. (2014). IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 124: 99-110
7. Atkins, MB, Lotze, MT, Dutcher, JP, Fisher, RI, Weiss, G, Margolin, K et al. (1999). High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105-2116. (Pubitemid 29318842
8. Rosenberg, SA, Yang, JC, Topalian, SL, Schwartzentruber, DJ, Weber, JS, Parkinson, DR et al. (1994). Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907-913
9. Dooms, H and Abbas, AK (2010). Revisiting the role of IL-2 in autoimmunity. Eur J Immunol 40: 1538-1540
10. Shevach, EM (2012). Application of IL-2 therapy to target T regulatory cell function. Trends Immunol 33: 626-632
11. Kennedy-Nasser, AA, Ku, S, Melenhorst, J, Barrett, J, Hazrat, Y, Durett, AG, et al. (2012). Ultra low-dose IL-2 mediated expansion of regulatory T cells as GvHD prophylaxis for recipients of allogeneic hematopoietic stem cells. ASBMT Tandem Meeting 2012
12. Kennedy-Nasser, AA, Ku, S, Castillo-Caro, P, Hazrat, Y, Wu, M-F, Liu, H, et al. (2014). Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 20: 2215-2225
13. Koreth, J, Matsuoka, K, Kim, HT, McDonough, SM, Bindra, B, Alyea, EP 3rd et al. (2011). Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365: 2055-2066
14. Matsuoka, K, Koreth, J, Kim, HT, Bascug, G, McDonough, S, Kawano, Y et al. (2013). Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 5: 179ra43
15. Matsuoka, K, Kim, HT, McDonough, S, Bascug, G, Warshauer, B, Koreth, J et al. (2010). Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 120: 1479-1493
16. Thornton, AM, Korty, PE, Tran, DQ, Wohlfert, EA, Murray, PE, Belkaid, Y et al. (2010). Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 184: 3433-3441
17. Akimova, T, Beier, UH, Wang, L, Levine, MH and Hancock, WW (2011). Helios expression is a marker of T cell activation and proliferation. PLoS ONE 6: E24226
18. Himmel, ME, MacDonald, KG, Garcia, RV, Steiner, TS and Levings, MK (2013). Helios+ and Helios-cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol 190: 2001-2008
19. Ayyoub, M, Raffin, C and Valmori, D (2013). Comment on "helios+ and helios-cells coexist within the natural FOXP3+ T regulatory cell subset in humans". J Immunol 190: 4439-4440
20. Dong, S, Maiella, S, Xhaard, A, Pang, Y, Wenandy, L, Larghero, J et al. (2013). Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. Blood 122: 1802-1812
21. MacDonald, KG, Han, JM, Himmel, ME, Huang, Q, Kan, B, Campbell, AI et al. (2013). Response to comment on "helios+ and helios-cells coexist within the natural FOXP3+ T regulatory cell subset in humans". J Immunol 190: 4440-4441
22. Raffin, C, Pignon, P, Celse, C, Debien, E, Valmori, D and Ayyoub, M (2013). Human memory Helios-FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1ß by downregulating their suppressor functions. J Immunol 191: 4619-4627
23. Setoguchi, R, Hori, S, Takahashi, T and Sakaguchi, S (2005). Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201: 723-735. (Pubitemid 40395118
24. Malek, TR and Castro, I (2010). Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity 33: 153-165
25. Pandiyan, P, Zheng, L, Ishihara, S, Reed, J and Lenardo, MJ (2007). CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8: 1353-1362. (Pubitemid 350131172
26. Yu, A, Zhu, L, Altman, NH and Malek, TR (2009). A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30: 204-217
27. Lopez-Vergès, S, Milush, JM, Pandey, S, York, VA, Arakawa-Hoyt, J, Pircher, H et al. (2010). CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 116: 3865-3874
28. Björkström, NK, Riese, P, Heuts, F, Andersson, S, Fauriat, C, Ivarsson, MA et al. (2010). Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116: 3853-3864
29. Caligiuri, MA, Zmuidzinas, A, Manley, TJ, Levine, H, Smith, KA and Ritz, J (1990). Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 171: 1509-1526. (Pubitemid 20167547
30. Freud, AG, Becknell, B, Roychowdhury, S, Mao, HC, Ferketich, AK, Nuovo, GJ et al. (2005). A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22: 295-304. (Pubitemid 40387472
31. Vosshenrich, CA, García-Ojeda, ME, Samson-Villéger, SI, Pasqualetto, V, Enault, L, Richard-Le Goff, O et al. (2006). A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 7: 1217-1224. (Pubitemid 44594318
32. Gasteiger, G, Hemmers, S, Bos, PD, Sun, JC and Rudensky, AY (2013). IL-2-dependent adaptive control of NK cell homeostasis. J Exp Med 210: 1179-1187
33. Martín-Fontecha, A, Thomsen, LL, Brett, S, Gerard, C, Lipp, M, Lanzavecchia, A et al. (2004). Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5: 1260-1265. (Pubitemid 41057741
34. Goldszmid, RS, Caspar, P, Rivollier, A, White, S, Dzutsev, A, Hieny, S et al. (2012). NK cell-derived interferon-© orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. Immunity 36: 1047-1059
35. Kerdiles, Y, Ugolini, S and Vivier, E (2013). T cell regulation of natural killer cells. J Exp Med 210: 1065-1068
36. Sitrin, J, Ring, A, Garcia, KC, Benoist, C and Mathis, D (2013). Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. J Exp Med 210: 1153-1165
37. Suthanthiran, M, Schwartz, JE, Ding, R, Abecassis, M, Dadhania, D, Samstein, B et al.; Clinical Trials in Organ Transplantation 04 (CTOT-04) Study Investigators. (2013). Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 369: 20-31
38. Askarieh, G, Alsiö, A, Pugnale, P, Negro, F, Ferrari, C, Neumann, AU et al.; DITTO-HCV and NORDynamIC Study Groups. (2010). Systemic and intrahepatic interferongamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 51: 1523-1530
39. Shimizu, K, Asakura, M and Fujii, S (2011). Prolonged antitumor NK cell reactivity elicited by CXCL10-expressing dendritic cells licensed by CD40L+ CD4+ memory T cells. J Immunol 186: 5927-5937
40. Weiss, GR, Grosh, WW, Chianese-Bullock, KA, Zhao, Y, Liu, H, Slingluff, CL Jr et al. (2011). Molecular insights on the peripheral and intratumoral effects of systemic highdose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 17: 7440-7450
41. Panelli, MC, Wang, E, Phan, G, Puhlmann, M, Miller, L, Ohnmacht, GA et al. (2002). Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 3: RESEARCH0035
42. Khor, CC, Vannberg, FO, Chapman, SJ, Guo, H, Wong, SH, Walley, AJ et al. (2010). CISH and susceptibility to infectious diseases. N Engl J Med 362: 2092-2101
43. Abbas, AK, Benoist, C, Bluestone, JA, Campbell, DJ, Ghosh, S, Hori, S et al. (2013). Regulatory T cells: Recommendations to simplify the nomenclature. Nat Immunol 14: 307-308
44. Canavan, JB, Afzali, B, Scottà, C, Fazekasova, H, Edozie, FC, Macdonald, TT et al. (2012). A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood 119: E57-e66
45. Fauriat, C, Long, EO, Ljunggren, HG and Bryceson, YT (2010). Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 115: 2167-2176
46. Kauffmann, A, Gentleman, R and Huber, W (2009). arrayQualityMetrics-A bioconductor package for quality assessment of microarray data. Bioinformatics 25: 415-416
47. Smyth, GK (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3
48. Benjamini, Y and Hochberg, Y (1995). Controlling the false discovery rate-A practical and powerful approach to multiple testing. J Roy Stat Soc B Met 57: 289-300.